Sexual wellness
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Kingsberg SA, Clayton AH, Portman D, et al. · Obstet Gynecol · 2019
PMID: 31599840 · DOI: 10.1097/AOG.0000000000003500
Summary
Two identical phase 3 randomized, double-blind, placebo-controlled trials (RECONNECT) in 1267 premenopausal women with HSDD; subcutaneous bremelanotide 1.75 mg as-needed vs placebo over 24 weeks. Primary endpoints: FSFI desire and FSDS-DAO item 13.
Citation hosted by NCBI. We link to the source so the researcher can read the abstract, full text, or references-cited list directly.
Compounds referenced in this study
- View product →PT-141Cyclic heptapeptide melanocortin agonist studied in libido and sexual-physiology research.
Guides covering this compound
More Sexual wellness citations
- Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire DisorderObstet Gynecol · 2019
- Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunctionInt J Impot Res · 2004
- Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to ViagraInt J Impot Res · 2004